Biogen (BIIB) PT Lowered to $195 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Biogen (BIIB) PT Lowered to $195 at Wedbush
January 12, 2022 6:46 AM EST
Yesterday, on January 11th, 2022, CMS posted a draft NCD proposing to cover approved anti-amyloid antibodies for Alzheimer's Disease under CED (coverage with evidence development) and only a randomized controlled trials.
Biogen's (NASDAQ: BIIB) Aduhelm is currently the only FDA approved therapy for Alzheimer's Disease, and such strict coverage rules are expected to significantly limit access to the drug.
Mizuho analyst Salim Syed removes nearly all Aduhelm sales from his model, as he lowers the price target on... More
January 12, 2022 6:27 AM EST
Needham & Company analyst Ami Fadia lowered the price target on Biogen (NASDAQ: BIIB) to $292.00 (from $328.00) while maintaining a Buy rating.
The analyst commented, "Following CMS's draft decision to cover monoclonal antibodies for treatment of Alzheimers disease under Coverage with Evidence... More
